192329-96-7

Basic information

• Product Name: 1,3-Piperazinedicarboxylic acid, 4-[[4-(4-bromophenoxy)phenyl]sulfonyl]-, 1-(1,1-dimethylethyl) ester
• CAS NO: 192329-96-7
• Molecular Formula: C22H25BrN2O7S
• Molecular Weight: 541.42
• Mol File: 192329-96-7.mol

Chemical Properties

• CAS DataBase Reference: 1,3-Piperazinedicarboxylic acid, 4-[[4-(4-bromophenoxy)phenyl]sulfonyl]-, 1-(1,1-dimethylethyl) ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Piperazinedicarboxylic acid, 4-[[4-(4-bromophenoxy)phenyl]sulfonyl]-, 1-(1,1-dimethylethyl) ester(192329-96-7)
• EPA Substance Registry System: 1,3-Piperazinedicarboxylic acid, 4-[[4-(4-bromophenoxy)phenyl]sulfonyl]-, 1-(1,1-dimethylethyl) ester(192329-96-7)

Safety Data

• Hazardous Substances Data: 192329-96-7(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 61405-25-2 4-(4-bromophenoxy)-benzenesulfonyl chloride 
• 3022-15-9 piperazine-2-carboxylic acid dihydrochloride 

Relevant articles and documents

Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof

The invention relates to compounds of the formula 1: wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder are carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of the formula I or a prodrug, salt of solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates. The invention still further relates to methods and intermediates useful for preparing these compounds, prodrugs, salts, and solvates.

Metalloproteinase inhibitors and intermediates useful for their preparation

PCT No. PCT/US96/19328 Sec. 371 Date Jun. 29, 1998 Sec. 102(e) Date Jun. 29, 1998 PCT Filed Dec. 5, 1996 PCT Pub. No. WO97/20824 PCT Pub. Date Jun. 12, 1997The invention relates to compounds of formula (1) wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder is carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of formula (1) or a prodrug, salt or solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates. The invention still further relates to methods and intermediates useful for preparing these compounds, prodrugs, salts, and solvates.

Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses

The invention relates to compounds of the formula I STR1 in which Q is a divalent radical having four ring atoms which together with C* and N form a six-membered ring, each of these four ring atoms being unsubstituted or substituted by a suitable substituent and at least one being a heteroatom selected from O, N and S, with the remainder being carbon atoms; and Ar is an aryl or heteroaryl group. The invention further relates to pharmaceutically acceptable prodrugs and pharmaceutically acceptable salts of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases, especially MMPs or TNF-α, by administering a compound of the formula I or a salt or prodrug thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, salts, and prodrugs.